CIIE helping Gilead Sciences boost development in China
China DailyGilead Sciences, a US-based biopharma company, is showcasing its latest innovative developments in virology, oncology and mycology and advancements in health equity at the ongoing seventh China International Import Expo in Shanghai. Over the past two years, Gilead accelerated the introduction of globally leading innovative drugs to Chinese patients, including the launch of new products for triple negative breast cancer and for invasive fungal diseases," said Jin Fangqian, vice-president of Gilead and the general manager for its China affiliate. To date, Gilead has launched 11 innovative drugs dedicated to areas such as HIV prevention and treatment, viral hepatitis, invasive fungal diseases and triple negative breast cancer in China, according to Jin. At the CIIE, the company also signed several collaboration agreements with partners including governments, local distributors and industry associations, to enhance drug access, improve treatment outcome and the quality of life for patients, and help to drive disease diagnosis and treatment, so as to support the advancement of the "Healthy China 2030" initiative, according to the company.
History of this topic
Opportunities embraced at CIIE
China Daily
World-leading healthcare companies to display latest innovations at 6th CIIE
China Daily
Gilead Sciences participates in CIIE for first time, brings new products
China Daily
Gilead Sciences participates in CIIE for first time, brings new products
China Daily
Gilead Sciences participates in CIIE for first time, brings new products
China DailyDiscover Related
